Trial Profile
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Bendamustine; Cytarabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 19 Feb 2020 Planned End Date changed from 30 Nov 2025 to 5 Feb 2025.
- 19 Feb 2020 Status changed from recruiting to active, no longer recruiting.